Skip to main content
Journal cover image

A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial.

Publication ,  Journal Article
Armstrong, PW; Rouleau, J-L
Published in: Can J Cardiol
July 2008

Congestive heart failure comprises a major public health problem destined to grow enormously over the next decade. Paradoxically, and in contrast to acute coronary disease, acute heart failure has been relatively understudied. Current standards of care involve the use of intravenous diuretics and vasodilators; inotropic agents have been restricted to in-hospital use because of concern about their potential harmful effects. The emergence of recombinant human B-type natriuretic peptide (BNP) provides an interesting therapeutic alternative because of its capacity to promote vasodilation as well as increase salt and water excretion, and improve pulmonary congestion by reducing left ventricular filling pressure. This agent will be explored in the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF), the largest ever trial conducted in acute decompensated heart failure. Patients will be studied through day 30 with end points of all-cause mortality in rehospitalization as the primary composite outcome. A variety of mechanistic substudies are planned as well as an assessment of the health care economic implications of acute heart failure and the pathophysiological elements hypothesized to modulate the expected treatment effect examined. The trial is embedded in an academic research organization motif and promises to provide a significant contribution to the body of knowledge in acute heart failure and the care of patients so afflicted.

Duke Scholars

Published In

Can J Cardiol

DOI

EISSN

1916-7075

Publication Date

July 2008

Volume

24 Suppl B

Issue

Suppl B

Start / End Page

30B / 32B

Location

England

Related Subject Headings

  • Treatment Outcome
  • Survival Analysis
  • Severity of Illness Index
  • Risk Assessment
  • Prognosis
  • Patient Selection
  • Natriuretic Peptide, Brain
  • Natriuretic Agents
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, P. W., & Rouleau, J.-L. (2008). A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial. Can J Cardiol, 24 Suppl B(Suppl B), 30B-32B. https://doi.org/10.1016/s0828-282x(08)71028-6
Armstrong, Paul W., and Jean-Lucien Rouleau. “A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial.Can J Cardiol 24 Suppl B, no. Suppl B (July 2008): 30B-32B. https://doi.org/10.1016/s0828-282x(08)71028-6.
Armstrong, Paul W., and Jean-Lucien Rouleau. “A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial.Can J Cardiol, vol. 24 Suppl B, no. Suppl B, July 2008, pp. 30B-32B. Pubmed, doi:10.1016/s0828-282x(08)71028-6.
Journal cover image

Published In

Can J Cardiol

DOI

EISSN

1916-7075

Publication Date

July 2008

Volume

24 Suppl B

Issue

Suppl B

Start / End Page

30B / 32B

Location

England

Related Subject Headings

  • Treatment Outcome
  • Survival Analysis
  • Severity of Illness Index
  • Risk Assessment
  • Prognosis
  • Patient Selection
  • Natriuretic Peptide, Brain
  • Natriuretic Agents
  • Male
  • Humans